Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

11%

1 trials in Phase 3/4

Results Transparency

0 of 7 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1

7(77.8%)

Phase 2

1(11.1%)

Phase 3

1(11.1%)

9Total

Phase 1(7)

Phase 2(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT06500793Phase 1Recruiting

Single Dose Study, Pharmacokinetics of Oxycodone and PF614 Co-Administered With Nafamostat (PF614-MPAR-102)

Role: lead

NCT06602271Phase 3Recruiting

PF614 Analgesic Activity in Acute Postoperative Pain (PF614-301)

Role: lead

NCT06629402Phase 2Completed

Assessment of PF614 Effects on Experimental Pain in the Cold Pressure Test (PF614-201)

Role: lead

NCT02454712Phase 1Completed

Study of PF614 Compared to OxyContin® in Healthy Volunteers (PF614-101)

Role: lead

NCT05090280Phase 1Completed

Pharmacokinetics of Oxycodone and PF614 Co-Administered with Nafamostat (PF614-MPAR-101)

Role: lead

NCT05043766Phase 1Completed

Evaluation of Oral PF614 Relative to OxyContin (PF614-102)

Role: lead

NCT04406415Phase 1Completed

Oral Nafamostat in Healthy Volunteers (NAF-101)

Role: lead

NCT05571345Phase 1Completed

A Study to Evaluate the Oral Abuse Potential of PF614 in Non-Dependent Recreational Opioid Users (PF614-104)

Role: lead

NCT05567354Phase 1Completed

A Study to Evaluate the Intranasal Abuse Potential of PF614 in Non-Dependent Recreational Opioid Users (PF614-103)

Role: lead

All 9 trials loaded